Bioanalysis Services
Bioanalytical solutions to progress your clinical research pipelines
Bioanalytical Solutions for Clinical Endpoints
With over two decades of experience, our bioanalytical laboratory strives to be at the forefront of scientific innovation, housing the tools and expertise required for successful compound development and market release.
Our large and small molecule bioanalytical services seamlessly integrate into your discovery, preclinical, and clinical phase development, delivering robust, accurate and reliable data endpoints to advance your therapeutic pipelines.
Bioanalytical Laboratory Services
Immunogenicity Assessment
Assessing the immunogenicity of therapeutic drugs is particularly important when considering the significance of anti-drug antibodies (ADA) in clinical studies. Our customisable assay panels are developed through rigorous method development and validation to ensure regulatory and sponsor-specific requirements are met, whilst simultaneously providing useful, clinically relevant data to facilitate the progression of your therapeutic pipeline.
PD Assays
Our PD assays, renowned for their sensitivity and specificity, are custom-developed and validated by our expert scientists, in collaboration with your team and according to your requirements. Assays are compatible with sample material from an extensive array of matrices and therefore are suitable for large-scale, high-throughput clinical bioanalysis studies.
PK/TK Analysis
Synexa’s comprehensive Pharmacokinetic (PK)/Toxicokinetic (TK) bioanalytical services meticulously assess absorption, distribution, metabolism, excretion and kinetics of toxic substances. Our expertise ensures that customers receive crucial insights, optimising drug safety and efficacy for successful therapeutic development.
Biosimilar Development
Synexa’s specialised bioanalytical labs, deep regulatory expertise and technical proficiencies make us the ideal partner for biosimilar therapeutic development. We tailor our services to each project, encompassing bioequivalence studies, anti-drug antibody (ADA) assessments and more. With a history of successful collaborations in clinical bioanalysis, we work closely with customers to navigate the complexities of biosimilar development while meeting stringent timelines and regulatory standards.
Regulatory Expertise
Our Experts Help You Navigate Complex Regulatory Requirements
Synexa supports pharmaceutical and biotechnology companies with regulated bioanalytical services aligned with global quality and compliance standards. Our teams follow validated processes and quality-driven workflows to deliver reliable bioanalytical data that supports confident clinical decision-making and regulatory readiness across every stage of development.overcome potential regulatory challenges due to evolving expectations for bioanalytical clinical data sets that could pose obstacles to regulatory approvals.
20+
Years of successfully passing regulatory inspections
Bioanalysis Platforms
Our technology platforms are robust, reliable and reputable in the clinical field and provide comprehensive and detailed data readouts for your application.
VICTOR® Nivo™
Multimode plate reader supporting fluorescence, luminescence and absorbance-based assays
Waters T-QS LC-MS/MS
Tandem mass spectrometry system for sensitive, quantitative small molecule bioanalysis
Sciex 6500+
Triple quadrupole mass spectrometer for highly sensitive, quantitative bioanalysis
Waters Premier I-Class UPLC
Ultra-performance liquid chromatography system delivering high-resolution compound separation
BD FacsLyric (12 colours)
Automated flow cytometry system enabling reproducible, high-throughput immunophenotyping
MSD S600
High-throughput electrochemiluminescence reader for sensitive multiplex biomarker detection
MSD SQ 120
Compact MSD reader enabling robust electrochemiluminescent immunoassays
Olink Signature q100
Proximity extension assay platform for highly specific, multiplexed protein biomarker profiling
WIZARD2 gammacounter
Gamma counter for sensitive radioisotope detection in ligand binding and PK assays
Biacore T200 GxP SPR
Label-free surface plasmon resonance system for real-time biomolecular interaction and binding kinetics analysis
Envision Xcite
Multimode plate reader supporting luminescence, fluorescence and absorbance-based bioassays
Gyrolab xPlore
Automated nanolitre-scale immunoassay platform for rapid, low-volume protein biomarker analysis
FAQ
Can Synexa develop custom bioanalytical assays for complex studies?
Yes. Synexa specialises in designing and validating bespoke assays tailored to your therapeutic and study requirements. Our scientists leverage advanced platforms and innovative strategies to overcome challenges such as assay interference and matrix effects.
What bioanalytical platforms does Synexa use for assay development?
Synexa leverages advanced analytical platforms, including LC-MS/MS, MSD electrochemiluminescence, ELISA, AlphaLISA, DELFIA, luminescence, fluorescence/FRET, and Gyrolab. These technologies enable us to deliver sensitive, robust, and custom-designed assays tailored to your study requirements.
How does Synexa ensure the accuracy and reliability of bioanalytical assays?
All Synexa assays undergo rigorous validation following the latest regulatory guidelines. Key parameters include precision, accuracy, selectivity, specificity, stability, and drug tolerance. This meticulous approach guarantees high-quality, reproducible data for pharmacokinetics, immunogenicity, and pharmacodynamic studies.
What makes Synexa a trusted partner for regulated bioanalysis services?
Synexa Life Sciences brings over 20 years of expertise in developing and validating complex bioanalytical assays for large molecules, including monoclonal antibodies, bispecifics, and peptides. Our assays are designed to meet FDA and EMA guidelines, ensuring precision, accuracy, and regulatory compliance at every stage of clinical development.
More on Regulated Bioanalysis
GMP Grade Ligand Binding and Potency Assays – Frequently Asked Questions
EBF OS 2025: My Key Highlights
Where Does Bioanalysis Fit into Drug Discovery Pipelines?
Navigating IVDR in Clinical Trials: What’s Changed, and Why It Matters
Navigating IVDR in Clinical Trials: What’s Changed, and Why It Matters
Where Does Bioanalysis Fit into Drug Discovery Pipelines?
EBF OS 2025: My Key Highlights
Bridging the gap between science and life.
Contact Us
Discuss real solutions to develop your therapeutic pipeline.
